Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.61 |
| ▸ | JAK1 | P23458 | 3/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25427796 | 0.81 | HSD11B1 (0.41) | HSD11B1JAK1MAP2K1POLBNAMPT | |
| SCHEMBL30509712 | 0.81 | HSD11B1 (0.41) | HSD11B1JAK1MAP2K1POLBNAMPT | |
| SCHEMBL30509683 | 0.81 | HSD11B1 (0.42) | HSD11B1JAK1MAP2K1POLBNAMPT | |
| SCHEMBL25428242 | 0.81 | HSD11B1 (0.42) | HSD11B1JAK1MAP2K1POLBNAMPT | |
| SCHEMBL12509444 | 0.79 | HSD11B1 (0.62) | HSD11B1MAP2K1POLBNAMPTDTYMK | |
| SCHEMBL25429671 | 0.77 | HSD11B1 (0.42) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL30509700 | 0.77 | HSD11B1 (0.42) | HSD11B1MAP2K1POLBDTYMKJAK3 | |
| SCHEMBL30268860 | 0.76 | GPR119 (0.48) | POLBNAMPTGPR119 | |
| SCHEMBL25426035 | 0.76 | CYP11B2 (0.39) | HSD11B1MAP2K1POLBNAMPTDTYMK | |
| SCHEMBL30509709 | 0.76 | CYP11B2 (0.39) | HSD11B1MAP2K1POLBNAMPTDTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321317-B1 | FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-24 | — | — | EP | disclosed |
| US-8486964-B2 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | MERCK PATENT GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110172265-A1 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-2321317-A1 | FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010022850-A1 | FUSED PYRROLIDINO-CYCLOPROPANE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172265-A1 | Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885JAK1 3793/4885MAP2K1 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.